Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies

• Status: Recruiting
• Trial end date: 2024-12-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a single arm, phase II trial of HLA-haploidentical related hematopoietic cells transplant (Haplo-HCT) using reduced intensity conditioning (fludarabine and melphalan and total body irradiation). Peripheral blood is the donor graft source. This study is designed to estimate disease-free survival (DFS) at 18 months post-transplant.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute
• Treatments: Fludarabine; Fludarabine phosphate; Melphalan; Vidarabine

Criteria

Inclusion Criteria:

• Age ≥ 55 years or HCT Co-Morbidity score (HCT-CI) >/=3

• Lack of a suitable 8/8 HLA-matched sibling donor

• Adequate performance status is defined as Karnofsky score ≥ 70%

• Patients and selected donor must be HLA typed at high resolution using DNA based typing at the following HLA-loci: HLA-A, -B, -C and DRB1. Donors must be HLA-haploidentical relatives including, but not limited to, children, siblings, or parents, defined as having a shared HLA haplotype between donor and patient at HLA-A, -B, -C, and -DRB1.

• Acute Myeloid Leukemia (AML): Must be in remission with morphology (<5% blasts)

• Acute Lymphoblastic Leukemia (ALL)/lymphoma second or greater complete remission (CR) first CR unable to tolerate consolidation chemotherapy due to chemotherapy-related toxicities, first CR high-risk ALL

• Biphenotypic/Undifferentiated/Prolymphocytic Leukemias in first or subsequent CR

• Myelodysplastic syndrome: any subtype including refractory anemia (RA) if severe pancytopenia or complex cytogenetics. Blasts must be less than 5%. If 5% of more requires chemotherapy for cytoreduction to
• Chronic Myelogenous leukemia in accelerated phase: patient must have failed at least two different Tyrosine Kinase Inhibitor (TKI)s, been intolerant to all TKIs, or have T315l mutation

• Myeloproliferative neoplasms/myelofibrosis: Blasts must be less than 5%. If 5% or more requires chemotherapy for cytoreduction to
• Relapsed large-cell lymphoma, mantle-cell lymphoma or Hodgkin lymphoma that is chemotherapy sensitive and has failed or ineligible for an autologous transplant

• Burkitt's lymphoma in second CR or subsequent CR

• Relapsed T-cell lymphoma that is chemotherapy sensitive in CR/Partial Response (PR) that has failed or ineligible for an autologous transplant

• Natural killer cell malignancies

• Relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), marginal zone B-cell lymphoma, follicular lymphoma with any of the following:

• Progressed within 12 months of achieving a partial or complete remission Patients who had remissions lasting up

• Patients who had remission lasting > 12 months are eligible after at least two prior therapies

• Patients with primary, refractory disease. Bulky disease and an estimated tumor doubling time of less than one month require debulking therapy prior to transplant.

• Lymphoplasmacytic lymphoma is eligible after initial therapy if chemotherapy sensitive

• Adequate organ function as defined per protocol

• Sexually active females of child bearing potential and males with partners of child bearing potential must agree to use adequate birth control during study treatment

Exclusion Criteria:

• Pregnant or breastfeeding

• Untreated active infection

• Active HIV infection

• Prior allogenic transplant at any time prior or less than 6 months since prior autologous transplant (if applicable)

• Active central nervous system malignancy

• Favorable risk AML defined as per protocol

• Active central nervous system malignancy

• Favorable risk AML defined as having one of the following:

• t(8,21) without cKIT mutation or evidence of immunophenotypic, cytogenetic or molecular minimal residual disease (MRD)

• inv(16) or t(16;16) without cKIT mutation or evidence of MRD

• Normal karyotype with mutated NPM1 but FLT3-ITD wild type without evidence of MRD

• Normal karyatype with double mutated CEBPA without evidence of MRD